Drug intelligence / Profile preview

Ambela

Development stage: Unknown
Lead developer: Espad Pharmed Daru
Administration: Intradermal

Overview

Ambela is an aesthetic injectable product, specifically a dermal filler, developed and marketed by the Iranian company Espad Pharmed Daru. It is designed for use in cosmetic dermatology to address facial aging concerns, including the correction of wrinkles, fine lines, and volume loss. Ambela is positioned within Espad Pharmed's Beauty portfolio, which features a range of aesthetic solutions such as other filler brands (e.g., Lunafil, Fiorage) and skin rejuvenation products. As a dermal filler, Ambela functions by providing mechanical volume and structural support to the skin's dermal layers, thereby smoothing the skin surface and restoring youthful contours.

Brand names: Ambela
Other names: امبلا

Targets

APMAP (Adipocyte plasma membrane-associated protein)

Beyond the preview

Go deeper on Ambela.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ambela.

Explore the full profile